Search for a trial

A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO COMPARE THE EFFICACY AND SAFETY OF POMALIDOMIDE, BORTEZOMIB AND LOW-DOSE DEXAMETHASONE VERSUS BORTEZOMIB AND LOW-DOSE DEXAMETHASONE IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA

Study ObjectivesTo compare the efficacy of POM + BTZ + LD-DEX with BTZ + LD-DEX in subjects with relapsed or refractory MM Secondary Objectives:To evaluate the safety and additional efficacy of POM + BTZ + LD-DEX versus BTZ + LD-DEX in subjects with…

Natural Killer cell alloreactive bone marrow transplantation for Multiple Myeloma

The aim of the study is demonstrating that progression free survival will improve after KIR-mismatched haploidentical bone marrow transplantation.

Causes and consequences of disrupted bone marrow function following autologous stem cell transplantation, a pilot study

The present study will be focused on defining the mechanisms that contribute to the increased vulnerability of HSPC for chemotherapy. In particular DNA damage response, ROS production and protective mechanism against stress response (NFR2) will be…

A single center, randomized, double-blind, 3-arm parallel Phase I study to assess pharmacokinetics, safety and tolerability of MYL-1402O solution for intravenous infusion after 90 minute intravenous infusion at one dose level (equivalent weight-adjusted dose (1 mg/kg) compared to the EU and US marketed drug product (Avastin®) in healthy male volunteers.

The purpose of the study is to assess the concentrations of bevacizumab in the blood at different times after the volunteers have been administered MYL-14020 or Avastin® . In addition, it will be investigated to what extent MYL-10420 is tolerated.…

A phase 1B multicenter, open-label study to determine the recommended dose and regimen of Durvalumab (MEDI4736) either as monotherapy or in combination with Pomalidomide (POM) with or without low-dose Dexamethasone (DEX) in subjects with relapsed and refractory multiple myeloma (RRMM)

Primary ObjectiveThe primary objective of the study is to determine the recommended dose and regimen ofdurvalumab either as monotherapy or in combination with POM +/- dex in subjects with RRMM.Secondary ObjectivesThe secondary objectives are to:*…

In vitro Screening of drug candidates against cancer and autoimmune diseases for effects on human blood cells

Primary Objective: Test the capacity of drug candidates to specifically inhibit the signalling pathways they target in human blood cells in vitro in the setting of human whole blood.Secondary Objective(s): Test whether drug candidates exert…